Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Double-blind, placebo controlled randomized study of co-administering testosterone with PDE5 [phosphodiesterase V] inhibitors in patients non-responders to PDE5 inhibitors alone

Trial Profile

Double-blind, placebo controlled randomized study of co-administering testosterone with PDE5 [phosphodiesterase V] inhibitors in patients non-responders to PDE5 inhibitors alone

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Apr 2013

At a glance

  • Drugs Testosterone (Primary) ; Tadalafil
  • Indications Erectile dysfunction
  • Focus Therapeutic Use
  • Acronyms TADTEST
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 27 Dec 2012 New source identified and integrated (German Clinical Trials Register; DRKS00004081).
    • 08 May 2009 Results presented at the 104th Annual Meeting of the American Urological Association (AUA), 2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top